Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
International Journal of Clinical Oncology
Erschienen in: International Journal of Clinical Oncology 10/2023

29.06.2023 | Special Article

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

verfasst von: Satoru Muto, Takeshi Matsubara, Takamitsu Inoue, Hiroshi Kitamura, Kazuhiro Yamamoto, Taisuke Ishii, Masahiko Yazawa, Ryohei Yamamoto, Naoto Okada, Kiyoshi Mori, Hiroyuki Yamada, Takashige Kuwabara, Atsushi Yonezawa, Takuya Fujimaru, Haruna Kawano, Hideki Yokoi, Kent Doi, Junichi Hoshino, Motoko Yanagita

Erschienen in: International Journal of Clinical Oncology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of CKD may be higher in patients with cancer than in those without due to the addition of cancer-specific risk factors to those already present for CKD. In this review, we describe the evaluation of kidney function in patients undergoing anticancer drug therapy. When anticancer drug therapy is administered, kidney function is evaluated to (1) set the dose of renally excretable drugs, (2) detect kidney disease associated with the cancer and its treatment, and (3) obtain baseline values for long-term monitoring. Owing to some requirements for use in clinical practice, a GFR estimation method such as the Cockcroft–Gault, MDRD, CKD-EPI, and the Japanese Society of Nephrology’s GFR estimation formula has been developed that is simple, inexpensive, and provides rapid results. However, an important clinical question is whether they can be used as a method of GFR evaluation in patients with cancer. When designing a drug dosing regimen in consideration of kidney function, it is important to make a comprehensive judgment, recognizing that there are limitations regardless of which estimation formula is used or if GFR is directly measured. Although CTCAEs are commonly used as criteria for evaluating kidney disease-related adverse events that occur during anticancer drug therapy, a specialized approach using KDIGO criteria or other criteria is required when nephrologists intervene in treatment. Each drug is associated with the different disorders related to the kidney. And various risk factors for kidney disease associated with each anticancer drug therapy.
Literatur
1.
2.
GBD Chronic Kidney Disease Collaboration (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395:709–733
3.
Rosner MH, Perazella MA (2017) Acute kidney injury in patients with cancer. N Engl J Med 376:1770–1781PubMedCrossRef
4.
5.
Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376–1384PubMedCrossRef
6.
Lane BR, Demirjian S, Derweesh IH et al (2015) Survival and Functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate. Eur Urol 68:996–1003PubMedCrossRef
7.
Nakamura Y, Tsuchiya K, Nitta K et al (2011) Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality. Jpn J Nephrol 53:38–45 (Japanese)
8.
Launay-Vacher V (2010) Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 30:548–556PubMedCrossRef
9.
Torres da Costa ESV, Costalonga EC, Coelho FO et al (2018) Assessment of kidney function in patients with cancer. Adv Chronic Kidney Dis 25:49–56CrossRef
10.
11.
Lien YH, Lai LW (2011) Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol 7:85–95PubMedCrossRef
12.
Wada T, Ishimoto T, Nakaya I et al (2021) A digest of the evidence-based clinical practice guideline for nephrotic syndrome 2020. Clin Exp Nephrol 25:1277–1285PubMedCrossRef
13.
14.
Leppert JT, Lamberts RW, Thomas IC et al (2018) Incident CKD after radical or partial nephrectomy. J Am Soc Nephrol 29:207–216PubMedCrossRef
15.
Ohira S, Abe K, Nagayama M et al (1991) Tumor markers in hemodialysis patients. J Jpn Soc Dial Ther 24:475–483 (Japanese)CrossRef
16.
Hanafusa N, Tsuruya K, Komaba H (2019) Toseki Kanja No Kensa Chi No Yomikata, 4th edn. Nihon Medical Center (Japanese)
17.
Bellizzi V, de Nicola L, Ames P et al (1997) Fetal proteins and chronic treatment with low-dose erythropoietin. J Lab Clin Med 129:193–199PubMedCrossRef
18.
Yang Y, Li HY, Zhou Q et al (2016) Renal function and all-cause mortality risk among cancer patients. Medicine (Baltimore) 95:e3728PubMedCrossRef
19.
Ishii T, Fujimaru T, Nakano E et al (2020) Association between chronic kidney disease and mortality in stage IV cancer. Int J Clin Oncol 25:1587–1595PubMedCrossRef
20.
Chen DP, Davis BR, Simpson LM et al (2017) Association between chronic kidney disease and cancer mortality: a report from the ALLHAT. Clin Nephrol 87(2017):11–20PubMedCrossRef
21.
22.
Canet E, Zafrani L, Lambert J et al (2013) Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS ONE 8:e55870PubMedPubMedCentralCrossRef
23.
Funakoshi T, Horimatsu T, Nakamura M et al (2018) Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open 3:e000301PubMedPubMedCentralCrossRef
24.
25.
Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRef
26.
Rosner MH, Jhaveri KD, McMahon BA et al (2021) Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin 71:47–77PubMedCrossRef
27.
Hoxha E, Wiech T, Stahl PR et al (2016) A mechanism for cancer-associated membranous nephropathy. N Engl J Med 374:1995–1996PubMedCrossRef
28.
Leeaphorn N, Kue APP, Thamcharoen N et al (2014) Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol 40:29–35PubMedCrossRef
29.
Yokoyama H, Taguchi T, Sugiyama H et al (2012) Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 16:557–563PubMedCrossRef
30.
31.
Lawrence HJ, Simone J, Aur RJ (1975) Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. Cancer 36:1572–1576PubMedCrossRef
32.
Chao CT, Wang CY, Lai CF et al (2014) Dialysis-requiring acute kidney injury increases risk of long-term malignancy: a population-based study. J Cancer Res Clin Oncol 140:613–621PubMedCrossRef
33.
Maisonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93–99PubMedCrossRef
34.
Butler AM, Olshan AF, Kshirsagar AV et al (2015) Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis 65:763–772PubMedPubMedCentralCrossRef
35.
Kaidu K, Tanaka Y, Tokui N (2013) The relationship between hemodialysis patients and cancer. Diagn Treat 101:1071–1076 (Japanese)
36.
37.
Chien CC, Han MM, Chiu YH et al (2017) Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer 8:9–18PubMedPubMedCentralCrossRef
38.
Shlipak MG, Fried LF, Crump C et al (2003) Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87–92PubMedCrossRef
39.
Muntner P, Hamm LL, Kusek JW et al (2004) The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140:9–17PubMedCrossRef
40.
Grulich AE, van Leeuwen MT, Falster MO et al (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67PubMedCrossRef
41.
de Fijter JW (2017) Cancer and mTOR inhibitors in transplant recipients. Transplantation 101:45–55PubMedCrossRef
42.
Farrugia D, Mahboob S, Cheshire J et al (2014) Malignancy-related mortality following kidney transplantation is common. Kidney Int 85:1395–1403PubMedCrossRef
43.
Ying T, Shi B, Kelly PJ et al (2020) Death after kidney transplantation: an analysis by era and time post-transplant. J Am Soc Nephrol 31:2887–2899PubMedPubMedCentralCrossRef
44.
45.
Imamura R, Nakazawa S, Yamanaka K et al (2021) Cumulative cancer incidence and mortality after kidney transplantation in Japan: a long-term multicenter cohort study. Cancer Med 10:2205–2215PubMedCrossRef
46.
Imao T, Ichimaru N, Takahara S et al (2007) Risk factors for malignancy in Japanese renal transplant recipients. Cancer 109:2109–2115PubMedCrossRef
47.
Eccher A, Girolami I, Motter JD et al (2020) Donor-transmitted cancer in kidney transplant recipients: a systematic review. J Nephrol 33:1321–1332PubMedPubMedCentralCrossRef
48.
Noone AM, Pfeiffer RM, Dorgan JF et al (2019) Cancer-attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014. Cancer 125:2647–2655PubMedCrossRef
49.
Yanik EL, Siddiqui K, Engels EA (2015) Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis. Cancer Med 4:1448–1459PubMedPubMedCentralCrossRef
50.
Knoll GA, Kokolo MB, Mallick R et al (2014) Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349:g6679PubMedPubMedCentralCrossRef
51.
Budde K, Lehner F, Sommerer C et al (2015) Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant 15:119–128PubMedCrossRef
52.
Hahn D, Hodson EM, Hamiwka LA et al (2019) Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 12:CD004290PubMed
53.
Webster AC, Lee VW, Chapman JR et al (2006) Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81:1234–1248PubMedCrossRef
54.
Malyszko J, Lee MW, Capasso G et al (2020) How to assess kidney function in oncology patients. Kidney Int 97:894–903PubMedCrossRef
55.
Casal MA, Nolin TD, Beumer JH (2019) Estimation of kidney function in oncology: implications for anticancer drug selection and dosing. Clin J Am Soc Nephrol 14:587–595PubMedPubMedCentralCrossRef
56.
Capasso A, Benigni A, Capitanio U et al (2019) Summary of the international conference on onco-nephrology: an emerging field in medicine. Kidney Int 96:555–567PubMedCrossRef
57.
58.
Krens SD, Lassche G, Jansman FGA et al (2019) Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 20:e200–e207PubMedCrossRef
59.
Okuda Y, Hamada R, Uemura O et al (2021) Mean of creatinine clearance and urea clearance examined over 1 h estimates glomerular filtration rate accurately and precisely in children. Nephrology (Carlton) 26:763–771PubMedCrossRef
60.
Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMedCrossRef
61.
Tattersall J, Dekker F, Heimbürger O et al (2011) When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant 26:2082–2086PubMedCrossRef
62.
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
63.
Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254PubMedCrossRef
64.
65.
Killeen AA, Ashwood ER, Ventura CB et al (2013) Recent trends in performance and current state of creatinine assays. Arch Pathol Lab Med 137:496–502PubMedCrossRef
66.
Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRef
67.
Horio M (2012) Chronic kidney disease (CKD) recent progress. Topics: IV. assessment of renal function. J Jpn Soc Internal Med 101:1259–1265CrossRef
68.
Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20–29PubMedPubMedCentralCrossRef
69.
Hudson JQ, Nolin TD (2018) Pragmatic use of kidney function estimates for drug dosing: the tide is turning. Adv Chronic Kidney Dis 25:14–20PubMedCrossRef
70.
Funakoshi Y, Fujiwara Y, Kiyota N et al (2016) Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. Cancer Chemother Pharmacol 77:281–288PubMedPubMedCentralCrossRef
71.
Funakoshi Y, Fujiwara Y, Kiyota N et al (2013) Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Jpn J Clin Oncol 43:271–277PubMedCrossRef
72.
Shibata K, Yasuda Y, Kobayashi R et al (2015) Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1. Clin Exp Nephrol 19:1107–1113PubMedCrossRef
73.
Kos J, Werle B, Lah T et al (2000) Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Mark 15:84–89CrossRef
74.
75.
Du Bois D, Du Bois EF (1916) Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Internal Med XVII:863–871CrossRef
76.
(2012) Clinical practice Guidebook for Diagnosis and Treatment of Chronic Kidney Diasease 2012. Tokyo-igakusha [Japanese]
77.
Horie S, Oya M, Nangaku M et al (2018) Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 22:210–244PubMedCrossRef
78.
Launay-Vacher V, Spano JP, Janus N et al (2009) Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 70:124–133PubMedCrossRef
79.
80.
Motzer RJ, Hutson TE, Olsen MR et al (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30:1371–1377PubMedCrossRef
81.
Willeke F, Horisberger K, Kraus-Tiefenbacher U et al (2007) A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 96:912–917PubMedPubMedCentralCrossRef
82.
Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714–1768PubMedCrossRef
83.
Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939PubMedCrossRef
84.
Khan G, Golshayan A, Elson P et al (2010) Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 21:1618–1622PubMedCrossRef
85.
Cassidy J, Twelves C, Van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575PubMedCrossRef
86.
Ha SH, Park JH, Jang HR et al (2014) Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function. BMC Cancer 14:906PubMedPubMedCentralCrossRef
87.
88.
Hanna RM, Barsoum M, Arman F et al (2019) Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int 96:572–580PubMedCrossRef
89.
Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30:187–200PubMedPubMedCentralCrossRef
90.
Usui J, Glezerman IG, Salvatore SP et al (2014) Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol 45:1918–1927PubMedCrossRef
91.
Izzedine H, Massard C, Spano JP et al (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46:439–448PubMedCrossRef
92.
Perazella MA, Shirali AC (2020) Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int 97:62–74PubMedCrossRef
93.
Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142PubMedCrossRef
94.
Eijgelsheim M, Sprangers B (2020) Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor-associated acute kidney injury: PRO. Kidney360 1:158–161PubMedPubMedCentralCrossRef
95.
Gutgarts V, Glezerman IG (2020) Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor-associated acute kidney injury: CON. Kidney360 1:162–165PubMedPubMedCentralCrossRef
96.
Doi K, Nishida O, Shigematsu T et al (2018) The Japanese clinical practice guideline for acute kidney injury 2016. Clin Exp Nephrol 22:985–1045PubMedPubMedCentralCrossRef
97.
Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179–c184PubMedCrossRef
98.
Manohar S, Kompotiatis P, Thongprayoon C et al (2019) Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant 34:108–117PubMedCrossRef
99.
Japanese Society of nephrology (JSN), Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and The Japanese Society of Nephrology and Pharmacotherapy (JSNP) (2022) Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022, Life Science Co Ltd, Tokyo [Japanese]
100.
101.
Nishikubo M, Shimomura Y, Hiramoto N et al (2021) Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. BMC Nephrol 22:175PubMedPubMedCentralCrossRef
102.
Ulusakarya A, Misra S, Haydar M et al (2010) Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol 27:1425–1426PubMedCrossRef
103.
Mahmood F, Matar M, Davis A (2014) Renal failure and hypocalcaemia secondary to cabazitaxel treatment for prostate cancer. J Clin Diagn Res 2:1–3CrossRef
104.
Zuber J, Martinez F, Droz D et al (2002) Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 81:321–331PubMedCrossRef
105.
106.
Kaneko T, Shimizu A, Aoki M et al (2015) A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep 4:31–37PubMedCrossRef
107.
Maruyama K, Chinda J, Kuroshima T et al (2015) Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med 54:823–826PubMedCrossRef
108.
Calizo RC, Bhattacharya S, van Hasselt JGC et al (2019) Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun 10:2061PubMedPubMedCentralCrossRef
109.
110.
Cvitkovic E, Spaulding J, Bethune V et al (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357–1361PubMedCrossRef
111.
Sato K, Watanabe S, Ohtsubo A et al (2016) Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16:222PubMedPubMedCentralCrossRef
112.
Adams M, Kerby IJ, Rocker I et al (1989) A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol 28:57–60PubMedCrossRef
113.
Mangioni C, Bolis G, Pecorelli S et al (1989) Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81:1464–1471PubMedCrossRef
114.
Lévi F, Metzger G, Massari C et al (2000) Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38:1–21PubMedCrossRef
115.
Sutton RA, Walker VR, Halabe A et al (1991) Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med 117:40–43PubMed
116.
Lam M, Adelstein DJ (1986) Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8:164–169PubMedCrossRef
117.
Swainson CP, Colls BM, Fitzharris BM (1985) Cis-platinum and distal renal tubule toxicity. N Z Med J 98:375–378PubMed
118.
Portilla D, Li S, Nagothu KK et al (2006) Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 69:2194–2204PubMedCrossRef
119.
Oeffinger KC, Hudson MM (2004) Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 54:208–236PubMedCrossRef
120.
Vickers AE, Rose K, Fisher R et al (2004) Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32:577–590PubMedCrossRef
121.
Tanaka H, Ishikawa E, Teshima S et al (1986) Histopathological study of human cisplatin nephropathy. Toxicol Pathol 14:247–257PubMedCrossRef
122.
Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50:147–158PubMedCrossRef
123.
Manohar S, Bansal A, Wanchoo R et al (2019) Ibrutinib induced acute tubular injury: a case series and review of the literature. Am J Hematol 94:E223-e225PubMedCrossRef
124.
Crona DJ, Faso A, Nishijima TF et al (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609–619PubMedPubMedCentralCrossRef
125.
Ando Y (2023) Chapter 3: Management of kidney injury caused by anticancer drug therapy, from clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol [manuscript in submission]
126.
Nissim I, Horyn O, Daikhin Y et al (2006) Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 66:7824–7831PubMedCrossRef
127.
Ensergueix G, Pallet N, Joly D et al (2020) Ifosfamide nephrotoxicity in adult patients. Clin Kidney J 13:660–665PubMedCrossRef
128.
Skinner R, Sharkey IM, Pearson AD et al (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11:173–190PubMedCrossRef
129.
Oberlin O, Fawaz O, Rey A et al (2009) Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol 27:5350–5355PubMedCrossRef
130.
Stöhr W, Paulides M, Bielack S et al (2007) Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 48:447–452PubMedCrossRef
131.
132.
Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer 82:1636–1645PubMedPubMedCentral
133.
Ho PT, Zimmerman K, Wexler LH et al (1995) A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 76:2557–2564PubMedCrossRef
134.
Akilesh S, Juaire N, Duffield JS et al (2014) Chronic ifosfamide toxicity: kidney pathology and pathophysiology. Am J Kidney Dis 63:843–850PubMedCrossRef
135.
Yaseen Z, Michoudet C, Baverel G et al (2008) In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro. Pediatr Nephrol 23:611–618PubMedCrossRef
136.
Hanly L, Rieder MJ, Huang SH et al (2013) N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. J Popul Ther Clin Pharmacol 20:e132-145PubMed
137.
Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694–703PubMedCrossRef
138.
Abelson HT, Fosburg MT, Beardsley GP et al (1983) Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1:208–216PubMedCrossRef
139.
Amitai I, Rozovski U, El-Saleh R et al (2020) Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol 38:584–588PubMedCrossRef
140.
Widemann BC, Balis FM, Kempf-Bielack B et al (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100:2222–2232PubMedCrossRef
141.
Zattera T, Londrino F, Trezzi M et al (2017) Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J Nephropathol 6:43–48PubMedCrossRef
142.
Stavroulopoulos A, Nakopoulou L, Xydakis AM et al (2010) Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 32:1000–1004PubMedCrossRef
143.
Vootukuru V, Liew YP, Nally JV Jr (2006) Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 23:419–422PubMedCrossRef
144.
Rombolà G, Vaira F, Trezzi M et al (2015) Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage. J Nephrol 28:187–191PubMedCrossRef
145.
Visser S, Huisbrink J, van ’t Veer NE, et al (2018) Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J 52:1800884PubMedCrossRef
146.
Assayag M, Rouvier P, Gauthier M et al (2017) Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed. BMC Cancer 17:770PubMedPubMedCentralCrossRef
147.
Saif MW, Xyla V, Makrilia N et al (2009) Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf 8:257–260PubMedCrossRef
148.
Leal F, Macedo LT, Carvalheira JB (2014) Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series. J Chemother 26:169–172PubMedCrossRef
149.
Izzedine H, Isnard-Bagnis C, Launay-Vacher V et al (2006) Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 21:3038–3045PubMedCrossRef
150.
Al-Nouri ZL, Reese JA, Terrell DR et al (2015) Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125:616–618PubMedPubMedCentralCrossRef
151.
McCarthy JT, Stoats BA (1986) Pulmonary hypertension, hemolytic anemia, and renal failure: a mitomycin-associated syndrome. Chest 89:608–611PubMedCrossRef
152.
El-Ghazal R, Podoltsev N, Marks P et al (2011) Mitomycin–C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer 10:142–145PubMedCrossRef
153.
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154PubMedCrossRef
154.
Ault BH, Stapleton FB, Gaber L et al (1988) Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 319:1397–1400PubMedCrossRef
155.
Gallon L, Perico N, Dimitrov BD et al (2006) Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF Am J Transplant 6:1617–1623PubMedCrossRef
156.
Anglicheau D, Pallet N, Rabant M et al (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 70:1019–1025PubMedCrossRef
157.
Paluri RK, Sonpavde G, Morgan C et al (2019) Renal toxicity with mammalian target of rapamycin inhibitors: a meta-analysis of randomized clinical trials. Oncol Rev 13:455PubMedPubMedCentralCrossRef
158.
Dimopoulos M, Alegre A, Stadtmauer EA et al (2010) The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116:3807–3814PubMedCrossRef
159.
Niesvizky R, Naib T, Christos PJ et al (2007) Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 138:640–643PubMedCrossRef
160.
Specter R, Sanchorawala V, Seldin DC et al (2011) Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 26:881–886PubMedCrossRef
161.
Glezerman IG, Kewalramani T, Jhaveri K (2008) Reversible Fanconi syndrome due to lenalidomide. NDT Plus 1:215–217PubMedPubMedCentral
162.
Batts ED, Sanchorawala V, Hegerfeldt Y et al (2008) Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 49:1108–1115PubMedCrossRef
163.
Matsubara T, Yanagita M (2018) Nephrotoxicity of chemotherapy agents. J Jpn Soc Int Med 107:865–871 (Japanese)CrossRef
164.
Khurana A (2007) Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 5:341–344PubMedCrossRef
165.
Winn SK, Ellis S, Savage P et al (2009) Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 24:673–675PubMedCrossRef
166.
Cortes JE, Gambacorti-Passerini C, Kim DW et al (2017) Effects of bosutinib treatment on renal function in patients with philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk 17:684-695.e686PubMedCrossRef
167.
Brosnan EM, Weickhardt AJ, Lu X et al (2014) Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 120:664–674PubMedCrossRef
168.
169.
Jhaveri KD, Sakhiya V, Fishbane S (2015) Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol 1:1133–1134PubMedCrossRef
170.
Teuma C, Perier-Muzet M, Pelletier S et al (2016) New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Cancer Chemother Pharmacol 78:419–426PubMedCrossRef
171.
Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435PubMedPubMedCentralCrossRef
172.
Espi M, Teuma C, Novel-Catin E et al (2021) Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. Eur J Cancer 147:29–39PubMedCrossRef
173.
Kitchlu A, Jhaveri KD, Wadhwani S et al (2021) A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep 6:66–77PubMedCrossRef
174.
Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638–647PubMedPubMedCentralCrossRef
175.
Mamlouk O, Selamet U, Machado S et al (2019) Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7:2PubMedPubMedCentralCrossRef
176.
Meguro S, Nagata T, Yokoyama K et al (1984) Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C. Invest New Drugs 2:381–385PubMedCrossRef
177.
Pollera CF, Ceribelli A, Crecco M et al (1994) Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs 12:111–119PubMedCrossRef
178.
Lund B, Hansen OP, Theilade K et al (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530–1533PubMedCrossRef
179.
Levitt ML, Kassem B, Gooding WE et al (2004) Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms. Lung Cancer 43:335–344PubMedCrossRef
180.
Daviet F, Rouby F, Poullin P et al (2019) Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol 85:403–412PubMedCrossRef
181.
Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428PubMedPubMedCentralCrossRef
182.
Mani S, Todd M, Poo WJ (1996) Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol 19:187–189PubMedCrossRef
183.
Ravandi F, Estrov Z, Kurzrock R et al (1999) A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res 5:3990–3998PubMed
184.
Zhao T, Wang X, Xu T et al (2017) Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: a systematic review and comprehensive meta-analysis. Oncotarget 8:51492–51506PubMedPubMedCentralCrossRef
185.
Saito H, Fukuhara T, Furuya N et al (2019) Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20:625–635PubMedCrossRef
186.
Van Wynsberghe M, Flejeo J, Sakhi H et al (2021) Nephrotoxicity of anti-angiogenic therapies. Diagnostics (Basel) 11:640PubMedCrossRef
187.
Fujita T, Hirayama T, Ishii D et al (2018) Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. Mol Clin Oncol 9:394–398PubMedPubMedCentral
188.
Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127PubMedCrossRef
189.
McCoach CE, Yu A, Gandara DR, et al (2021) Phase I/II study of capmatinib plus erlotinib in patients with MET-positive non-small-cell lung cancer. JCO Precis Oncol 1
190.
Akamatsu H, Toi Y, Hayashi H et al (2021) Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: west japan oncology group 8715L phase 2 randomized clinical trial. JAMA Oncol 7:386–394PubMedPubMedCentralCrossRef
191.
Kazandjian D, Blumenthal GM, Yuan W et al (2016) FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res 22:1307–1312PubMedCrossRef
192.
Giroux L, Bettez P, Giroux L (1985) Mitomycin-C nephrotoxicity: a clinico-pathologic study of 17 cases. Am J Kidney Dis 6:28–39PubMedCrossRef
193.
Fung MC, Storniolo AM, Nguyen B et al (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023–2032PubMedCrossRef
194.
Müller S, Schütt P, Bojko P et al (2005) Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 84:110–114PubMedCrossRef
195.
Shah M, Jenis EH, Mookerjee BK et al (1998) Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 83:1938–1946PubMedCrossRef
196.
Pfister F, Amann K, Daniel C et al (2018) Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology 73:990–1001PubMedCrossRef
197.
Person F, Rinschen MM, Brix SR et al (2019) Bevacizumab-associated glomerular microangiopathy. Mod Pathol 32:684–700PubMedCrossRef
198.
Izzedine H, Mangier M, Ory V et al (2014) Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85:457–470PubMedCrossRef
199.
den Deurwaarder ES, Desar IM, Steenbergen EJ et al (2012) Kidney injury during VEGF inhibitor therapy. Neth J Med 70:267–271
200.
Milan A, Puglisi E, Ferrari L et al (2014) Arterial hypertension and cancer. Int J Cancer 134:2269–2277PubMedCrossRef
201.
Kidoguchi S, Sugano N, Tokudome G et al (2021) New concept of onco-hypertension and future perspectives. Hypertension 77:16–27PubMedCrossRef
202.
Ranpura V, Pulipati B, Chu D et al (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23:460–468PubMedCrossRef
203.
Hatake K, Doi T, Uetake H et al (2016) Bevacizumab safety in Japanese patients with colorectal cancer. Jpn J Clin Oncol 46:234–240PubMedCrossRef
204.
Bæk Møller N, Budolfsen C, Grimm D et al (2019) Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment. Int J Mol Sci 20:4712PubMedPubMedCentralCrossRef
205.
Azizi M, Chedid A, Oudard S (2008) Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358:95–97PubMedCrossRef
206.
Grossman E, Messerli FH (2008) Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 10:556–566PubMedCrossRef
207.
Dickerson T, Wiczer T, Waller A et al (2019) Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 134:1919–1928PubMedPubMedCentralCrossRef
208.
Waxman AJ, Clasen S, Hwang WT et al (2018) Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol 4:e174519PubMedCrossRef
209.
Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108–2121PubMedCrossRef
210.
Stinchcombe TE, Jänne PA, Wang X et al (2019) Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 5:1448–1455PubMedPubMedCentralCrossRef
211.
Tojo A, Kyo T, Yamamoto K et al (2017) Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. Int J Hematol 106:385–397PubMedCrossRef
212.
(2019) Electrolytes and acid-base imbalances. In: Ahn W et al (eds) Pocket nephrology, Oncology. Wolters Kluwer, pp 9–33
213.
Garla VV, Salim S, Kovvuru KR, et al (2018) Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy. BMJ Case Rep 2018
214.
215.
Doshi SM, Shah P, Lei X et al (2012) Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 59:222–228PubMedCrossRef
216.
Sørensen JB, Andersen MK, Hansen HH (1995) Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 238:97–110PubMedCrossRef
217.
Bartalis E, Gergics M, Tinusz B et al (2021) Prevalence and prognostic significance of hyponatremia in patients with lung cancer: systematic review and meta-analysis. Front Med (Lausanne) 8:671951PubMedCrossRef
218.
Berghmans T, Paesmans M, Body JJ (2000) A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 8:192–197PubMedCrossRef
219.
Seethapathy H, Rusibamayila N, Chute DF et al (2021) Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant 36:2241–2247PubMedCrossRef
220.
Oronsky B, Caroen S, Oronsky A et al (2017) Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol 80:895–907PubMedPubMedCentralCrossRef
221.
Khan MI, Dellinger RP, Waguespack SG (2018) Electrolyte disturbances in critically ill cancer patients: an endocrine perspective. J Intensive Care Med 33:147–158PubMedCrossRef
222.
Spasovski G, Vanholder R, Allolio B et al (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 170:G1-47PubMedCrossRef
223.
Gralla RJ, Ahmad F, Blais JD et al (2017) Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Cancer Med 6:723–729PubMedPubMedCentralCrossRef
224.
Vassal G, Rubie H, Kalifa C et al (1987) Hyponatremia and renal sodium wasting in patients receiving cisplatinum. Pediatr Hematol Oncol 4:337–344PubMedCrossRef
225.
Pham PC, Reddy P, Qaqish S et al (2017) Cisplatin-induced renal salt wasting requiring over 12 liters of 3% saline replacement. Case Rep Nephrol 2017:8137078PubMedPubMedCentral
226.
Berardi R, Torniai M, Lenci E et al (2019) Electrolyte disorders in cancer patients: a systematic review. J Cancer Metastasis Treat 5:79
227.
Seo MS, Hwang IC, Jung J et al (2020) Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study. BMC Palliat Care 19:94PubMedPubMedCentralCrossRef
228.
Salahudeen AK, Doshi SM, Shah P (2013) The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center. Support Care Cancer 21:1871–1878PubMedCrossRef
229.
230.
Garofeanu CG, Weir M, Rosas-Arellano MP et al (2005) Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 45:626–637PubMedCrossRef
231.
Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373–379PubMedCrossRef
232.
Rosner MH, Dalkin AC (2012) Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol 7:1722–1729PubMedCrossRef
233.
Perazella MA, Eisen RN, Frederick WG et al (1993) Renal failure and severe hypokalemia associated with acute myelomonocytic leukemia. Am J Kidney Dis 22:462–467PubMedCrossRef
234.
235.
Gupta S, Seethapathy H, Strohbehn IA et al (2020) Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B cell lymphoma. Am J Kidney Dis 76:63–71PubMedPubMedCentralCrossRef
236.
Foster BJ, Clagett-Carr K, Leyland-Jones B et al (1985) Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 12(Suppl A):43–49PubMedCrossRef
237.
Ikari A, Okude C, Sawada H et al (2008) TRPM6 expression and cell proliferation are up-regulated by phosphorylation of ERK1/2 in renal epithelial cells. Biochem Biophys Res Commun 369:1129–1133PubMedCrossRef
238.
Wang Q, Qi Y, Zhang D et al (2015) Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol 36:3471–3482PubMedCrossRef
239.
Workeneh BT, Uppal NN, Jhaveri KD et al (2021) Hypomagnesemia in the cancer patient. Kidney360 2:154–166PubMedCrossRef
240.
Klempner SJ, Aubin G, Dash A et al (2014) Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 19:1008–1010PubMedPubMedCentralCrossRef
241.
Lin YT, Wang YF, Yang JC et al (2014) Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 9:1720–1725PubMedCrossRef
242.
243.
244.
Brade WP, Herdrich K, Varini M (1985) Ifosfamide–pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1–47PubMedCrossRef
245.
Hensley ML, Schuchter LM, Lindley C et al (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333–3355PubMedCrossRef
246.
Hensley ML, Hagerty KL, Kewalramani T et al (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27:127–145PubMedCrossRef
247.
Fukuoka M, Si N, Masuda N et al (1991) Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117:473–478PubMedCrossRef
248.
Sakurai M, Saijo N, Shinkai T et al (1986) The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol 16:153–156PubMedCrossRef
249.
Vose JM, Reed EC, Pippert GC et al (1993) Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 11:1306–1310PubMedCrossRef
250.
Guleria AS, Yang JC, Topalian SL et al (1994) Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 12:2714–2722PubMedCrossRef
251.
Belldegrun A, Webb DE, Austin HA 3rd et al (1987) Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106:817–822PubMedCrossRef
252.
253.
254.
Chappell JC, Turner PK, Pak YA et al (2019) Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. Clin Pharmacol Ther 105:1187–1195PubMedCrossRef
255.
Gupta S, Caza T, Herrmann SM et al (2022) Clinicopathologic features of acute kidney injury associated with CDK4/6 inhibitors. Kidney Int Rep 7:618–623PubMedCrossRef
256.
Christiansen CF, Johansen MB, Langeberg WJ et al (2011) Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med 22:399–406PubMedCrossRef
257.
Salahudeen AK, Doshi SM, Pawar T et al (2013) Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol 8:347–354PubMedCrossRef
258.
Duan ZY, Liu JQ, Yin P et al (2018) Impact of aging on the risk of platinum-related renal toxicity: a systematic review and meta-analysis. Cancer Treat Rev 69:243–253PubMedCrossRef
259.
Miyoshi T, Uoi M, Omura F et al (2021) Risk factors for cisplatin-induced nephrotoxicity: a multicenter retrospective study. Oncology 99:105–113PubMedCrossRef
260.
Mohri J, Katada C, Ueda M et al (2018) Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. J Transl Int Med 6:32–37PubMedPubMedCentralCrossRef
261.
Inai H, Kawai K, Ikeda A et al (2013) Risk factors for chronic kidney disease after chemotherapy for testicular cancer. Int J Urol 20:716–722PubMedCrossRef
262.
de Jongh FE, van Veen RN, Veltman SJ et al (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88:1199–1206PubMedPubMedCentralCrossRef
263.
Uchida M, Kondo Y, Suzuki S et al (2019) Evaluation of acute kidney injury associated with anticancer drugs used in gastric cancer in the Japanese Adverse Drug Event Report Database. Ann Pharmacother 53:1200–1206PubMedCrossRef
264.
Farry JK, Flombaum CD, Latcha S (2012) Long term renal toxicity of ifosfamide in adult patients–5 year data. Eur J Cancer 48:1326–1331PubMedCrossRef
265.
de Rouw N, Boosman RJ, van de Bruinhorst H et al (2020) Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 146:30–35PubMedCrossRef
266.
Kitchlu A, McArthur E, Amir E et al (2019) Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study. J Natl Cancer Inst 111:727–736PubMedCrossRef
267.
Petrelli F, Borgonovo K, Cabiddu M et al (2012) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11(Suppl 1):S9-19PubMedCrossRef
268.
Streb J, Püsküllüoğlu M, Glanowska I et al (2015) Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature. Oncol Lett 10:3749–3755PubMedPubMedCentralCrossRef
269.
Fakih MG, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6:152–156PubMedCrossRef
270.
Zhu X, Wu S, Dahut WL et al (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186–193PubMedCrossRef
271.
Cappagli V, Moriconi D, Bonadio AG et al (2021) Proteinuria is a late-onset adverse event in patients treated with cabozantinib. J Endocrinol Invest 44:95–103PubMedCrossRef
272.
Meraz-Muñoz A, Amir E, Ng P et al (2020) Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 8:e000467PubMedPubMedCentralCrossRef
273.
Shimamura Y, Watanabe S, Maeda T et al (2021) Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study. Clin Exp Nephrol 25:479–487PubMedCrossRef
274.
Zheng K, Qiu W, Wang H et al (2020) Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thorac Cancer 11:1746–1751PubMedPubMedCentralCrossRef
275.
Galfetti E, Cerutti A, Ghielmini M et al (2020) Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol Toxicol 21:19PubMedPubMedCentralCrossRef
276.
Ben Ayed W, Ben Said A, Hamdi A et al (2020) Toxicity, risk factors and management of cisplatin-induced toxicity: a prospective study. J Oncol Pharm Pract 26:1621–1629PubMedCrossRef
277.
Kidera Y, Kawakami H, Sakiyama T et al (2014) Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE 9:e101902PubMedPubMedCentralCrossRef
278.
Mizuno T, Ishikawa K, Sato W et al (2013) The risk factors of severe acute kidney injury induced by cisplatin. Oncology 85:364–369PubMedCrossRef
279.
van der Vorst M, Neefjes ECW, Toffoli EC et al (2019) Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer 19:1066PubMedPubMedCentralCrossRef
280.
Okamoto K, Saito Y, Narumi K et al (2020) Non-steroidal anti-inflammatory drugs are a risk factor for cisplatin-induced nephrotoxicity: a meta-analysis of retrospective studies. Anticancer Res 40:1747–1751PubMedCrossRef
281.
Yamamoto Y, Watanabe K, Matsushita H et al (2017) Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer. J Obstet Gynaecol Res 43:1880–1886PubMedCrossRef
282.
Patimarattananan T, Nongnuch A, Pattaranutaporn P et al (2021) Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin. Support Care Cancer 29:877–887PubMedCrossRef
283.
Almanric K, Marceau N, Cantin A et al (2017) Risk factors for nephrotoxicity associated with cisplatin. Can J Hosp Pharm 70:99–106PubMedPubMedCentral
284.
Liu JQ, Cai GY, Wang SY et al (2018) The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly. Ther Clin Risk Manag 14:1279–1285PubMedPubMedCentralCrossRef
285.
Motwani SS, McMahon GM, Humphreys BD et al (2018) Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol 36:682–688PubMedPubMedCentralCrossRef
286.
Komaki K, Kusaba T, Tanaka M et al (2017) Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study. BMC Cancer 17:144PubMedPubMedCentralCrossRef
287.
Burns CV, Edwin SB, Szpunar S et al (2021) Cisplatin-induced nephrotoxicity in an outpatient setting. Pharmacotherapy 41:184–190PubMedCrossRef
288.
Stewart DJ, Dulberg CS, Mikhael NZ et al (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40:293–308PubMedCrossRef
289.
Lauritsen J, Mortensen MS, Kier MGG et al (2015) Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol 26:173–178PubMedCrossRef
290.
Zhang KJ, Hanna NH, Althouse SK et al (2020) Risk factors for acute kidney injury during high-dose chemotherapy and outcomes for patients with relapsed germ cell tumors. Clin Genitourin Cancer 18:e585–e587PubMedCrossRef
291.
Park SE, Hwang JH, Choi JH et al (2019) Incidence, risk factors, and clinical outcomes of acute kidney injury caused by palliative chemotherapy in lung cancer. J Cancer 10:5332–5338PubMedPubMedCentralCrossRef
292.
García-Carro C, Bolufer M, Bury R et al (2022) Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant 37:887–894PubMed
293.
Stein C, Burtey S, Mancini J et al (2021) Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant 36:1664–1674PubMedCrossRef
294.
Seethapathy H, Zhao S, Chute DF et al (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1692–1700PubMedPubMedCentralCrossRef
Metadaten
Titel
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
verfasst von
Satoru Muto
Takeshi Matsubara
Takamitsu Inoue
Hiroshi Kitamura
Kazuhiro Yamamoto
Taisuke Ishii
Masahiko Yazawa
Ryohei Yamamoto
Naoto Okada
Kiyoshi Mori
Hiroyuki Yamada
Takashige Kuwabara
Atsushi Yonezawa
Takuya Fujimaru
Haruna Kawano
Hideki Yokoi
Kent Doi
Junichi Hoshino
Motoko Yanagita
Publikationsdatum
29.06.2023
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 10/2023
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-023-02372-4

Weitere Artikel der Ausgabe 10/2023

International Journal of Clinical Oncology 10/2023 Zur Ausgabe

Special Article

Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Original Article

Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study

Original Article

Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis

Correction

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Original Article

Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis

Original Article

Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise